Editas Medicine (EDIT) Accumulated Depreciation & Amortization (2016 - 2025)
Editas Medicine (EDIT) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $27.5 million as the latest value for Q3 2025.
- Quarterly Accumulated Depreciation & Amortization fell 9.77% to $27.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $27.5 million through Sep 2025, down 9.77% year-over-year, with the annual reading at $31.6 million for FY2024, 20.52% up from the prior year.
- Accumulated Depreciation & Amortization for Q3 2025 was $27.5 million at Editas Medicine, roughly flat from $27.7 million in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $31.6 million in Q4 2024, with the low at $12.0 million in Q1 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $23.2 million, with a median of $25.0 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 49.79% in 2021, then fell 9.77% in 2025.
- Over 5 years, Accumulated Depreciation & Amortization stood at $15.5 million in 2021, then surged by 38.81% to $21.5 million in 2022, then rose by 21.99% to $26.3 million in 2023, then increased by 20.52% to $31.6 million in 2024, then decreased by 12.96% to $27.5 million in 2025.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $27.5 million, $27.7 million, and $31.6 million for Q3 2025, Q1 2025, and Q4 2024 respectively.